By Ian Walker

 

AstraZeneca PLC said Tuesday that initial results from a trial of datopotamab deruxtecan-based combinations show promising clinical activity in patients with advanced non-small-cell lung cancer.

The pharmaceutical giant said that the trial showed encouraging efficacy and safety results that justify further studies.

Datopotamab deruxtecan is being jointly developed by AstraZeneca and Daiichi Sankyo.

"We look forward to continuing this important research with the goal of providing a new, effective treatment option for patients with advanced non-small-cell lung cancer," Astra's Chief Medical Officer and Oncology Chief Development Officer Cristian Massacesi said.

 

Write to Ian Walker at ian.walker@wsj.com

 

(END) Dow Jones Newswires

August 09, 2022 06:34 ET (10:34 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Set 2022 a Ott 2022 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Ott 2021 a Ott 2022 Clicca qui per i Grafici di Astrazeneca